In documents posted online Tuesday, regulators laid out several options
for addressing safety risks, including withdrawing their use
for chemotherapy patients.
FDA will ask its panel of outside cancer experts Thursday what action it should take to address growing evidence that the drugs cause blood clots, tumor growth and death.
Thousand Oaks, Calif.-based Amgen saw U.S. sales of Aranesp fall nearly 20 percent last year to $3.2 billion, according to figures from IMS Health Inc.